HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Sponsor
Celgene

Protocol Number
CC-122-CLL-001

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Kite Pharma

Protocol Number
Kite Pharma KTE-C19-102

To Learn More Call
201-510-0910

HUMAN BIOLOGICAL MATERIAL RESEARCH

Sponsor
University of Nebraska

Protocol Number
Pro2016-0163

To Learn More Call
201-510-0910

Retrospective analysis of the outcomes of patients with neutropenic fever

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack Retrospective (Lymphoma)

To Learn More Call
201-510-0910

CHART 14R16: Clinical Outcomes in Non-Hodgkin Lymphoma and Post-Transplant Lymphoproliferative Disorder Patients with Pre-Existing Soild-Organ Transplants or Autoimmune Diseases

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Hackensack IMC Pro 00005613

To Learn More Call
201-510-0910

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

Sponsor
HackensackUMC

Protocol Number
Pro00005671

To Learn More Call
201-510-0910

PHASE 1/2 STUDY TO DETERMINE THE SAFET